NAT8 Variants, N-Acetylated Amino Acids, and Progression of CKD
Shengyuan Luo,Aditya Surapaneni,Zihe Zheng,Josef Coresh,Bing Yu,Eric Boerwinkle,Adrienne Tin,Inga Steinbrenner,Pascal Schlosser,Anna Köttgen,Eugene P. Rhee,Adriana M. Hung,Girish N. Nadkarni,Dan E. Arking,Morgan E. Grams
DOI: https://doi.org/10.2215/cjn.08600520
IF: 10.6233
2020-12-30
Clinical Journal of the American Society of Nephrology
Abstract:Background and objectives Genetic variants in NAT8 , a liver- and kidney-specific acetyltransferase encoding gene, have been associated with eGFR and CKD in European populations. Higher circulating levels of two NAT8 -associated metabolites, N- δ -acetylornithine and N-acetyl-1-methylhistidine, have been linked to lower eGFR and higher risk of incident CKD in the Black population. We aimed to expand upon prior studies to investigate associations between rs13538, a missense variant in NAT8 , N-acetylated amino acids, and kidney failure in multiple, well-characterized cohorts. Design, setting, participants, & measurements We conducted analyses among participants with genetic and/or serum metabolomic data in the African American Study of Kidney Disease and Hypertension (AASK; n =962), the Atherosclerosis Risk in Communities (ARIC) study ( n =1050), and Bio Me , an electronic health record–linked biorepository ( n =680). Separately, we evaluated associations between rs13538, urinary N-acetylated amino acids, and kidney failure in participants in the German CKD (GCKD) study ( n =1624). Results Of 31 N-acetylated amino acids evaluated, the circulating and urinary levels of 14 were associated with rs13538 ( P <0.05/31). Higher circulating levels of five of these N-acetylated amino acids, namely, N- δ -acetylornithine, N-acetyl-1-methylhistidine, N-acetyl-3-methylhistidine, N-acetylhistidine, and N2,N5-diacetylornithine, were associated with kidney failure, after adjustment for confounders and combining results in meta-analysis (combined hazard ratios per two-fold higher amino acid levels: 1.48, 1.44, 1.21, 1.65, and 1.41, respectively; 95% confidence intervals: 1.21 to 1.81, 1.22 to 1.70, 1.08 to 1.37, 1.29 to 2.10, and 1.17 to 1.71, respectively; all P values <0.05/14). None of the urinary levels of these N-acetylated amino acids were associated with kidney failure in the GCKD study. Conclusions We demonstrate significant associations between an NAT8 gene variant and 14 N-acetylated amino acids, five of which had circulation levels that were associated with kidney failure.
urology & nephrology